Effectiveness and safety of vedolizumab induction with or without budesonide in patients with moderately to severely active Crohn’s disease in Europe: a retrospective observational study

被引：0
|
作者：
Roni Weisshof
Stephan R. Vavricka
Lieven Pouillon
Fiona Braegger
Montserrat Roset
Nawal Bent-Ennakhil
Marc Ferrante
机构：
[1] Rambam Health Care Campus,Department of Gastroenterology
[2] University Hospital Zürich,Department of Gastroenterology and Hepatology
[3] Center for Gastroenterology and Hepatology AG,Department of Gastroenterology and Hepatology
[4] Department of Gastroenterology and Hepatology,undefined
[5] Imelda GI Clinical Research Center,undefined
[6] EUCAN Evidence Generation,undefined
[7] Takeda Pharmaceuticals International AG,undefined
[8] Glattpark-Opfikon,undefined
[9] IQVIA,undefined
[10] Real World Solutions,undefined
[11] University Hospitals Leuven,undefined
[12] KU Leuven,undefined
来源：
BMC Gastroenterology | / 23卷
关键词：
Budesonide; Crohn’s disease; Moderately to severely active crohn’s disease; Vedolizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Effectiveness and safety of vedolizumab induction with or without budesonide in patients with moderately to severely active Crohn's disease in Europe: a retrospective observational study
    Weisshof, Roni
    Vavricka, Stephan R.
    Pouillon, Lieven
    Braegger, Fiona
    Roset, Montserrat
    Bent-Ennakhil, Nawal
    Ferrante, Marc
    [J]. BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [2] A retrospective observational study on the effectiveness and safety of vedolizumab with or without budesonide induction therapy among patients with moderate-to-severe Crohn's disease
    Weisshof, R.
    Vavricka, S.
    Pouillon, L.
    Braegger, F.
    Roset, M.
    Bent-Ennakhil, N.
    Ferrante, M.
    [J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 : S317 - S318
  • [3] Efficacy and safety of vedolizumab SC in patients with moderately to severely active Crohn's disease: Results of the VISIBLE 2 study
    Vermeire, S.
    Sandborn, W.
    Baert, F.
    Danese, S.
    Kobayashi, T.
    Loftus, E. V., Jr.
    Bhatia, S.
    Kisfalvi, K.
    Rosario, M.
    Zhang, W.
    D'Haens, G.
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S020 - S021
  • [4] Efficacy and safety of vedolizumab subcutaneous formulation in patients with moderately to severely active Crohn's disease: Results of the VISIBLE 2 study
    Vermeire, S.
    Sandborn, W.
    Danese, S.
    Baert, F.
    Kobayashi, T.
    Loftus, E.
    Bhatia, S.
    Kisfalvi, K.
    Rosario, M.
    Zhang, W.
    D'Haens, G.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 : 115 - 115
  • [5] Safety of Ustekinumab With and Without Concomitant Corticosteroids or Immunosuppressants in Patients With Moderately to Severely Active Crohn's Disease
    Sands, Bruce E.
    Gasink, Christopher
    Jacobstein, Douglas
    Ott, Elyssa
    Lang, Yinghua
    Ramachandran, Paraneedharan
    Ghosh, Subrata
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S329 - S330
  • [6] COST-EFFECTIVENESS OF VEDOLIZUMAB COMPARED WITH USTEKINUMAB AS TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE IN THE UNITED STATES
    Zouraq, Azzabi, I
    Wilson, M.
    Hather, G.
    Curtis, R.
    Luo, M.
    Khalid, J. M.
    Minda, K.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A183 - A183
  • [7] EARLY ONSET OF RESPONSE WITH INTRAVENOUS VEDOLIZUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE TREATED IN THE VISIBLE 2 STUDY
    D'Haens, Geer
    Baert, Filip J.
    Danese, Silvio
    Kobayashi, Taku
    Loftus, Edward V.
    Sandborn, William J.
    Dornic, Quentin
    Lindner, Dirk
    Kisfalvi, Krisztina
    Marins, Ed G.
    Vermeire, Sevenne
    [J]. GASTROENTEROLOGY, 2021, 160 (06) : S352 - S352
  • [8] VEDOLIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: METHODOLOGY OF THE MULTICENTRE, PROSPECTIVE, OBSERVATIONAL SUNRISE STUDY USING INTESTINAL ULTRASONOGRAPHY AS A DISEASE MONITORING MODALITY
    Carter, D.
    Fiorino, G.
    Biedermann, P.
    Ferri, F.
    Neuhold, M.
    Novak, K. L.
    Kopylov, U.
    [J]. DIGESTIVE AND LIVER DISEASE, 2023, 55 : S163 - S164
  • [9] Safety of Ustekinumab With and Without Concomitant Corticosteroids or Immunosuppressants in Patients With Moderately-to-Severely Active Crohn's Disease
    Bruce, Sands
    Christopher, Gasink
    Douglas, Jacobstein
    Elyssa, Ott
    Lang Yinghua
    Paraneedharan, Ramachandran
    Subrata, Ghosh
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S24 - S24
  • [10] Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial
    Vermeire, Severine
    D'Haens, Geert
    Baert, Filip
    Danese, Silvio
    Kobayashi, Taku
    Loftus, Edward, V
    Bhatia, Siddharth
    Agboton, Christian
    Rosario, Maria
    Chen, Chunlin
    Zhang, Wenwen
    Kisfalvi, Krisztina
    Sandborn, William J.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 (01): : 27 - 38
12345